Abstract
Despite a paucity of high quality clinical data, methotrexate (MTX) remains one of the most commonly used medications in the treatment of patients with psoriatic arthritis (PsA). This report addresses mechanistic rationale, available clinical evidence, safety considerations, and a potential research agenda regarding the use of MTX in the management of PsA.
MeSH terms
-
Anti-Inflammatory Agents / adverse effects
-
Anti-Inflammatory Agents / therapeutic use*
-
Arthritis, Psoriatic / drug therapy*
-
Arthritis, Psoriatic / immunology
-
Biological Products / therapeutic use
-
Drug Therapy, Combination
-
Evidence-Based Medicine
-
Humans
-
Methotrexate / adverse effects
-
Methotrexate / therapeutic use*
-
Risk Assessment
-
Treatment Outcome
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Substances
-
Anti-Inflammatory Agents
-
Biological Products
-
Tumor Necrosis Factor-alpha
-
Methotrexate